- Home
- A-Z Publications
- Current Molecular Medicine
- Previous Issues
- Volume 9, Issue 6, 2009
Current Molecular Medicine - Volume 9, Issue 6, 2009
Volume 9, Issue 6, 2009
-
-
Editorial [Hot Topic: Tumor Immunology (Guest Editors: Bharat H. Joshi and Raj K. Puri)]
Authors: Bharat H. Joshi and Raj K. PuriConsiderable progress has been made in our understanding of host immune responses to cancer. This includes identification of antigens overexpressed on human tumors and antigen epitopes recognized by the cellular arm of the immune system (CD4+, CD8+ T and NK T-cell populations); identification and characterization of antigen presenting cells (e.g., dendritic cells); co-stimulatory requirements for effecti Read More
-
-
-
The Contrasting Roles of NKT Cells in Tumor Immunity
Authors: Jay A. Berzofsky and Masaki TerabeNKT cells are true T cells that serve as a bridge between the innate and adaptive immune system, acting as first responders. They recognize lipid antigens rather than peptides, and respond to these when presented by a non-classical class I MHC molecule, CD1d. NKT cells can play a pathogenic role in asthma or a protective role against several autoimmune diseases, in part based on their cytokine profile. In cancer, t Read More
-
-
-
Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Authors: Ulf Petrausch, Christian H. Poehlein, Shawn M. Jensen, Chris Twitty, James A. Thompson, Ilka Assmann, Sachin Puri, Michael G. LaCelle, Tarsem Moudgil, Levi Maston, Kevin Friedman, Sarah Church, Elisa Cardenas, Daniel P. Haley, Edwin B. Walker, Emmanuel Akporiaye, Andrew D. Weinberg, Sidney Rosenheim, Todd S. Crocenzi, Hong-Ming Hu, Brendan D. Curti, Walter J. Urba and Bernard A. FoxSince multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are s Read More
-
-
-
Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome
Authors: Caroline J. Voskens, Scott E. Strome and Duane A. SewellIn the vast majority of studies conducted to date, activation of cancer-specific T cell immunity through peptide-based immunization has failed to induce objective tumor regression. This failure is particularly troublesome given that these vaccines often stimulate T cell responses. In this review, we attempt to understand the relative failure of peptide cancer vaccines to achieve clinically meaningful responses. In the first part of t Read More
-
-
-
Lymphangiogenesis and Anti-Tumor Immune Responses
Authors: Michelle L. Varney, Seema Singh, Matthew Backora, Zhengtang Chen and Rakesh K. SinghTumor-induced immunosuppression is a fundamental problem in cancer immunotherapy and can occur by a variety of cellular and molecular mechanisms, affecting all arms of the immune system. Tumorproduced or elicited factors have been shown to inhibit antigen-specific immune effector function as well as impairment of the development, recruitment and maturation of dendritic cells (DCs) and T cells. A better und Read More
-
-
-
Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Authors: Benjamin Johnson, Takuya Osada, Timothy Clay, Herbert Lyerly and Michael MorseVascular endothelial growth factor (VEGF), known as a primary mediator of tumor-induced angiogenesis, is now understood to have a role in tumor-associated immunosuppression. Initially, VEGF was identified to alter the growth and maturation of the immature granulocyte-macrophage progenitors, and more recently it has been noted that it prevents dendritic cell (DC) precursors from developing into mature, antigenpre Read More
-
-
-
Dendritic Cells and their Receptors in Antitumor Immune Response
Authors: Raghvendra M. Srivastava and Ashok KharDCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Read More
-
-
-
Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer
Authors: Vedang Murthy, Aliasgar Moiyadi, Rajesh Sawant and Rajiv SarinSince the first reported clinical trial of Dendritic Cell Vaccine (DCV) in cancer in the mid nineties, few hundred clinical trials have been initiated and it was projected that over 3000 patients would be treated in DCV clinical trials by 2008. Despite extensive data to establish its safety, DCV remains an investigational approach, highlighting the need to undertake more meaningful proof of principle studies and more importantly, well desi Read More
-
-
-
A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Authors: Sachin Puri, Surbhi Puri, Ashok K. Mahapatra, Ejaz Hussain, Chitra Sarkar, Subrata Sinha and Bharat H. JoshiDespite advances in biomedical sciences, the prognosis of patients with brain tumors remains poor. Effective treatment is lacking for these central nervous system (CNS) cancers. Targeted immunotoxins are a new class of therapeutic approaches that have emerged for the treatment of human cancers. In this approach, tumor antigen or cell surface receptor is targeted by a chimeric fusion protein consisting of an antibody or a li Read More
-
-
-
The Signaling Function of the IL-13Rα2 Receptor in the Development of Gastrointestinal Fibrosis and Cancer Surveillance
Authors: Warren Strober, Atsushi Kitani, Stefan Fichtner-Feigl and Ivan J. FussThe IL-13Rα2 receptor is a high affinity receptor for IL-13 that is used only by IL-13 and is quite distinct from the well known IL-13Rα1 receptor that IL-13 shares with IL-4. It was widely considered to be a secreted receptor that is devoid of signaling activity and functional only as a decoy receptor that retarded signaling via IL-13Rα1. In recent studies, however, it was shown to be capable of robust signaling that results in production Read More
-
-
-
HLA Associations with Nasopharyngeal Carcinoma
Authors: Xin Li, Ross Fasano, Ena Wang, Kai-Tai Yao and Francesco M. MarincolaSeveral associations have been described between the frequency of human leukocyte antigen (HLA) class I genes in certain populations and the risk of developing nasopharyngeal carcinoma (NPC). Associations between ethnic background and geographic distribution, and relative disease incidence have been reported. Populations in geographical areas at higher risk of developing NPC display HLA distribution patterns differ Read More
-
-
-
HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Authors: Raed N. Samara and Samir N. KhleifHPV has been linked to many human malignancies and, as such, represents a major public health crisis. The understanding of HPV biology, however, has helped tremendously in developing prophylactic vaccines, which should help in decreasing mortality due to HPV infections. Understanding HPV biology has allowed researchers to use the virus as a model for the development of not only prophylactic vaccines, Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/cmm
Journal
10
5
false
en
